Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,636 | -69,792 | -53,795 | -36,798 | -17,715 |
| Depreciation Amortization | 10 | -2,631 | -2,275 | -1,663 | -901 |
| Other Working Capital | -2,798 | 3,110 | 2,150 | -714 | -1,708 |
| Other Operating Activity | 3,993 | 14,955 | 11,528 | 7,945 | 3,535 |
| Operating Cash Flow | $-16,431 | $-54,358 | $-42,392 | $-31,230 | $-16,789 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -7,589 | 23,106 | 34,655 | 28,145 | 7,942 |
| PPE Investments | N/A | -193 | -159 | -159 | -72 |
| Investing Cash Flow | $-7,589 | $22,913 | $34,496 | $27,986 | $7,870 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 19,934 | 25,738 | 421 | 384 | 23 |
| Financing Cash Flow | $19,934 | $25,738 | $421 | $384 | $23 |
| Beginning Cash Position | 16,856 | 22,563 | 22,563 | 22,563 | 22,563 |
| End Cash Position | 12,770 | 16,856 | 15,088 | 19,703 | 13,667 |
| Net Cash Flow | $-4,086 | $-5,707 | $-7,475 | $-2,860 | $-8,896 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,431 | -54,358 | -42,392 | -31,230 | -16,789 |
| Capital Expenditure | N/A | -193 | -159 | -159 | -72 |
| Free Cash Flow | -16,431 | -54,551 | -42,551 | -31,389 | -16,861 |